Cost effectiveness of continued-warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery.
Doug
D
Coyle
Kathryn
K
Coyle
Vidal
V
Essebag
David H
DH
Birnie
Kamran
K
Ahmad
Satish
S
Toal
John
J
Sapp
Jeffrey S
JS
Healey
Atul
A
Verma
George
G
Wells
Andrew D
AD
Krahn
D000925:Anticoagulants / Q000008:administration & dosage* / Q000191:economics; D002170:Canada; D003362:Cost-Benefit Analysis; D017147:Defibrillators, Implantable; D006406:Hematoma / Q000209:etiology; D006493:Heparin / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D007902:Length of Stay / Q000191:economics; D010138:Pacemaker, Artificial; D059035:Perioperative Period; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage* / Q000191:economics
D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin